Severe Disease Activity Based on the Paris Classification Is Associated with the Development of Extraintestinal Manifestations in Korean Children and Adolescents with Ulcerative Colitis

Hyo-Jeong Jang,1* Hyo Rim Suh,2* Sujin Choi,2 Suk Jin Hong,3 Seung-Man Cho,4 Kwang-Hae Choi,5 Byung-Ho Choe,6 Ben Kang,2 and on behalf of Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD)

1Department of Pediatrics, Keimyung University School of Medicine, Daegu, Korea
2Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, Korea
3Department of Pediatrics, Daegu Catholic University School of Medicine, Daegu, Korea
4Department of Pediatrics, Dongguk University School of Medicine, Gyeongju, Korea
5Department of Pediatrics, Yeungnam University School of Medicine, Daegu, Korea
6Department of Pediatrics, Yeungnam University School of Medicine, Daegu, Korea

ABSTRACT

Background: There are limited data regarding the extraintestinal manifestations (EIMs) associated with pediatric inflammatory bowel disease (IBD) in Korea. We aimed to investigate the clinical features and factors associated with the development of EIMs in Korean children and adolescents with IBD.

Methods: This multicenter, retrospective study was conducted from 2010 to 2017. Baseline clinicodemographic, laboratory findings, disease activity, disease phenotypes, and EIMs were investigated.

Results: A total of 172 patients were included. One-hundred thirty-seven (79.7%) had Crohn’s disease (CD), and 35 (20.3%) had ulcerative colitis (UC). EIMs occurred in 42 patients (24.4%). EIMs developed in 34/137 diagnosed with CD (24.8%), and in 8/35 diagnosed with UC (22.9%), during a median follow-up duration of 3.2 (interquartile range, 1.9–5.4) years for CD and 3.0 (1.0–4.0) years for UC, respectively. Arthritis/arthralgia was most commonly observed (n = 15, 35.7%), followed by stomatitis/oral ulcer (n = 10, 23.8%), hepatitis (n = 5, 11.9%), nephritis (n = 4, 9.5%), pancreatitis (n = 2, 4.8%), erythema nodosum (n = 2, 4.8%), pyoderma gangrenosum (n = 1, 2.4%), primary sclerosing cholangitis (n = 1, 2.4%), uveitis (n = 1, 2.4%), and ankylosing spondylitis (n = 1, 2.4%). A significant difference in disease severity based on the Paris classification (P = 0.011) and ESR at diagnosis (P = 0.043) was observed between the EIM positive and negative group in patients with UC. According to logistic regression analyses, S1 disease severity based on the Paris classification was the only factor that was significantly associated with the development of EIMs (odds ratio, 16.57; 95% confidence interval, 2.18–287.39; P = 0.017).

Conclusion: Severe disease activity based on the Paris classification in pediatric patients with UC was significantly associated with EIM development. As disease severity in the Paris classification is a dynamic parameter, treatment should be focused on disease control to minimize the occurrence of EIMs in Korean children and adolescents with UC.

Keywords: Extraintestinal Manifestation; Crohn’s Disease; Ulcerative Colitis; Pediatric; Paris Classification
INTRODUCTION

Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), are chronic, relapsing inflammatory disorders of the intestinal tract.\(^1\) IBD is systemic in nature, and extraintestinal manifestations (EIMs) are also commonly experienced by patients, with a reported incidence of 21–41%.\(^2\,3\) However, studies on pediatric EIMs are few, and limited research has shown that from one-quarter to almost one-half of pediatric patients with IBD experience at least 1 EIM at the time of diagnosis.\(^4\,6\)

EIMs are known to be more common in CD than UC,\(^3\) and usually correlate with disease activity, except for some exceptions.\(^7\) The pathogenesis of EIMs is poorly understood, and it has been speculated that several immune mechanisms are involved.\(^8\) The underlying immune dysregulation of IBD may target the entire body and not only the gastrointestinal (GI) tract. Although it is known that EIMs commonly occur in patients with pediatric-onset IBD, and it is presumed that the pathogenesis is closely related to the same mechanisms involved with the GI tract, few researchers have examined EIM rates and relationships to other disease-related factors in the clinical setting. Recently, the incidence and prevalence of pediatric IBD is increasing worldwide, including that of Korea.\(^9,10\) However, limited data exists for EIMs associated with pediatric IBD in Korea.

Therefore, we aimed to investigate the clinical features and factors associated with EIM development in Korean children and adolescents with IBD.

METHODS

Patients and study design

This study was a multicenter, retrospective study conducted from June 2010 to July 2017 at the Department of Pediatrics of four medical centers in the Daegu-Gyeongbuk region of Korea, which are the only tertiary referral centers for pediatric patients with IBD in the region: Kyungpook National University Children's Hospital, Keimyung University Dongsan Medical Center, Yeungnam University Medical Center, and Daegu Catholic University Medical Center. We analyzed the results of follow-up for the patients diagnosed within the study period.

This study included pediatric patients with IBD diagnosed before the age of 18 years. Diagnosis of IBD had been made in accordance with the revised Porto criteria of the European Society for Paediatric Gastroenterology Hepatology and Nutrition.\(^11\) Disease phenotype at diagnosis was classified according to the Paris classification.\(^12\) Clinico-demographics including sex, diagnosis age, growth indicators at diagnosis, previous history of EIMs, disease activity scores, laboratory test results, and medication were investigated for all the patients with available data at baseline and at EIM development. Physical examination, clinical activity scores, and laboratory tests, including complete blood cell counts with differential counts, chemistry profiles, erythrocyte sedimentation rate (ESR) and C-reactive protein levels, had been conducted at baseline and every regular visit, which had occurred in intervals of 1 week to 3 months or was an emergency visit. For the clinical activity scores at diagnosis and during follow-up, Pediatric Crohn's Disease Activity Index (PCDAI) had been checked in patients with CD,\(^13,14\) and Pediatric Ulcerative Colitis Activity Index (PUCAI) in patients with UC.\(^15\)
EIMs investigated for this study included ankylosing spondylitis, chronic active hepatitis, pancreatitis, nephritis/nephrotic syndrome, aphthous stomatitis, primary sclerosing cholangitis, arthralgia, arthritis, erythema nodosum, pyoderma gangrenosum, and iritis/uveitis. We also investigated EIMs involving the vascular, pulmonary, cardiac, and neurological systems. We did not include other potential EIMs related to nutrient deficiencies from malabsorption, such as osteopenia and osteoporosis; we also excluded fever of unknown origin and iatrogenic EIMs, such as drug-induced bone marrow suppression and corticosteroid-associated myopathy. We examined the EIM rates and the associations between EIMs and variables, and the possible association between a specific medical therapy and EIM development.

**Statistical analysis**

Student's t-test and Wilcoxon's rank-sum test were used for statistical comparison of continuous variables between groups and the χ² test or Fisher's exact test was used for comparison of categorical variables. Comparative data for continuous variables are expressed as medians with interquartile range (IQR) or means with standard deviation. Univariate and multivariate logistic regression analyses were performed to examine the association of the development of EIMs with variables. Univariate logistic regression analysis was performed to investigate the crude odds ratio (OR) for each variable, and those with a P value of < 0.1 in the univariate analysis were included in the multivariate analysis. The results are expressed as adjusted ORs with 95% confidence intervals (CIs). Statistical significance was defined as a P value of < 0.05. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA).

**Ethics statement**

This study was approved by the Institutional Review Board (IRB) of Kyungpook National University Chilgok Hospital and all other participating centers, and informed consent was waived due to the retrospective nature of this study (IRB No. 2018-03-023).

**RESULTS**

**Baseline characteristics of the patients**

A total of 172 patients were included in this study of whom 137 (79.7%) were CD, and 35 (20.3%) were UC patients, respectively. A total of 116 (67.4%) were male, whereas 56 (32.6%) were female patients. The mean age at diagnosis was 13.9 (IQR, 12.1–15.1) years.

**Development of EIMs in the patients**

EIMs developed in 42 patients among the total 172 patients (24.4%). EIMs developed in 34 patients among 137 diagnosed with CD (24.8%), and in 8 patients among 35 diagnosed with UC (22.9%) (P = 0.984). All patients with EIMs had developed only one EIM, and there were no patients that developed more than one EIM. The median follow-up duration was 3.2 (IQR, 1.9–5.4) years for patients with CD and 3.0 (1.0–4.0) years for patients with UC (P = 0.073). Arthritis or arthralgia was most commonly observed (n = 15, 35.7%), followed by stomatitis or oral ulcer (n = 10, 23.8%), hepatitis (n = 5, 11.9%), nephritis (n = 4, 9.5%), pancreatitis (n = 2, 4.8%), erythema nodosum (n = 2, 4.8%), pyoderma gangrenosum (n = 1, 2.4%), primary sclerosing cholangitis (n = 1, 2.4%), uveitis (n = 1, 2.4%), and ankylosing spondylitis (n = 1, 2.4%) (Table 1).
Arthritis, which was defined as pain and tenderness, swelling, redness and heat on physical examination with radiologic signs of inflammation in one or more joints, were noted in 5 (12.5%) patients at diagnosis and during follow-up. Among hepatitis, one patient was confirmed as autoimmune hepatitis and the others as non-specific hepatitis with hypertransaminasemia. The autoimmune hepatitis had developed in a patient with CD during treatment with mesalazine, which resolved after treatment with azathioprine. Among the EIMs with kidney involvement, two were confirmed as immunoglobulin A nephropathy with kidney biopsy, and both developed in patients with CD during treatment with infliximab. Pancreatitis was observed at diagnosis in two patients with CD, which resolved after treatment with exclusive enteral nutrition.

Comparisons between the EIM-positive and -negative groups
Comparisons of the variables between the EIM-positive and -negative groups in patients with CD were not statistically significant (Table 2). However, comparisons of the variables between the EIM-positive and -negative groups in patients with UC revealed a significant difference in disease severity based on the Paris classification and ESR levels at diagnosis. Patients with S1 disease severity based on the Paris classification were more likely to develop EIMs than those with S0 disease severity (P = 0.011), and higher ESR at diagnosis was significantly associated with the development of EIMs (P = 0.043) (Table 3). Meanwhile, PUCAI score at diagnosis was not significantly different between the EIM-positive and -negative groups in the patients with UC (Fig. 1A), despite the differences in PUCAI score between patients with S0 and S1 disease activity (Fig. 1B).

Factors associated with EIM development in patients with UC
According to univariate logistic regression analysis, S1 disease severity based on the Paris classification was significantly associated with EIM development (Table 4). S1 disease severity and ESR at diagnosis (P < 0.1) were included in the multivariate logistic regression analysis, which revealed that S1 disease severity based on the Paris classification was the only factor that was significantly associated with EIM development (OR, 16.57; 95% CI, 2.18–287.39; P = 0.017) (Table 4).

DISCUSSION
This is the first multicenter study to investigate the EIMs associated with pediatric IBD in Korea. We have revealed a novel finding that the disease severity of UC based on the Paris classification was significantly associated with EIM development. Close disease activity...
Table 2. Comparison between the EIM-positive and -negative groups in CD patients

| Variables                      | EIM-positive group (n = 34) | EIM-negative group (n = 103) | P       |
|--------------------------------|-----------------------------|------------------------------|---------|
| Male sex                       | 21 (61.8)                   | 77 (74.8)                    | 0.216   |
| Age at diagnosis, yr           | 13.9 (11.7–16.3)            | 14.1 (12.6–15.1)             | 0.929   |
| Age at maximum follow-up, yr   | 17.8 (15.1–20.3)            | 18.0 (15.6–20.3)             | 0.325   |
| Paris classification age       |                             |                              | 0.092   |
| A1a                            | 7 (6.8)                     | 6 (7.6)                      |         |
| A1b                            | 89 (86.4)                   | 24 (70.6)                    |         |
| A2                             | 7 (6.8)                     | 4 (11.8)                     |         |
| Lower GI tract location        |                             |                              | 0.523   |
| L1                             | 12 (11.7)                   | 2 (5.9)                      |         |
| L2                             | 6 (5.8)                     | 3 (8.8)                      |         |
| L3                             | 85 (82.5)                   | 29 (81.3)                    |         |
| Upper GI tract location        |                             |                              | 0.407   |
| No involvement                 | 40 (38.8)                   | 11 (29.4)                    |         |
| L4a                            | 20 (19.4)                   | 10 (29.4)                    |         |
| L4b                            | 18 (17.5)                   | 8 (23.5)                     |         |
| L4a+b                          | 25 (24.3)                   | 7 (20.6)                     |         |
| GI tract behavior              |                             |                              | 0.814   |
| B1                             | 87 (84.5)                   | 27 (79.4)                    |         |
| B2                             | 13 (12.6)                   | 6 (17.6)                     |         |
| B3/B2B3                        | 3 (2.9)                     | 1 (2.9)                      |         |
| Perianal modifiers             | 42 (41.7)                   | 18 (52.9)                    | 0.347   |
| Growth retardation             | 20 (19.4)                   | 12 (35.5)                    | 0.125   |
| PCDAI at diagnosis             | 42.5 (17.5–50)              | 42.5 (35.0–47.5)             | 0.547   |
| CRP at diagnosis, mg/dL        | 3.8 (1.9–6.6)               | 3.2 (0.3–3.6)                | 0.186   |
| ESR at diagnosis, mm/hr        | 44 (28–65)                  | 39.5 (20–74)                 | 0.405   |
| FC at diagnosis, mg/kg         | 526 (248–1,000)             | 350 (66–684)                 | 0.131   |

Data are expressed as median (interquartile range) for continuous variables that did not show normal distribution, unless otherwise indicated.

EIM = extraintestinal manifestation, CD = Crohn's disease, GI = gastrointestinal, A1a = 0–9 years, A1b = 10–16 years, A2 = ≤ 17 years, L1 = distal 1/3 ileum ± limited cecal disease, L2 = colonic disease, L3 = ileocolonic disease, L4a = upper disease proximal to ligament of Treitz, L4b = upper disease distal to the ligament of Treitz and proximal to the distal 1/3 ileum, L4a+b = upper disease involvement in both L4a and L4b, B1 = nonstricturing nonpenetrating behavior, B2 = stricturing behavior, B3 = penetrating behavior, B2B3 = both B2 and B3, PCDAI = Pediatric Crohn’s Disease Activity Index, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, FC = fecal calprotectin.

Table 3. Comparison between the EIM-positive and -negative groups in UC patients

| Variables                      | EIM-positive group (n = 8) | EIM-negative group (n = 27) | P       |
|--------------------------------|-----------------------------|-------------------------------|---------|
| Male sex                       | 21 (61.8)                   | 77 (74.8)                    | 0.216   |
| Age at diagnosis, yr           | 13.9 (11.7–16.3)            | 14.1 (12.6–15.1)             | 0.325   |
| Age at maximum follow-up, yr   | 17.8 (15.1–20.3)            | 18.0 (15.6–20.3)             | 0.678   |
| UC extent                      |                             |                              | 0.011   |
| E1                             | 1 (3.7)                     | 0 (0.0)                      |         |
| E2                             | 5 (18.5)                    | 0 (0.0)                      |         |
| E3                             | 4 (14.8)                    | 2 (25.0)                     |         |
| E4                             | 17 (63.0)                   | 6 (25.0)                     |         |
| UC severity                    |                             |                              |         |
| S0                             | 2 (25.0)                    | 21 (77.8)                    |         |
| S1                             | 6 (75.0)                    | 6 (22.2)                     |         |
| PCDAI at diagnosis             | 53.8 ± 18.1                 | 41.7 ± 17.5                  | 0.098   |
| CRP at diagnosis, mg/dL        | 0.5 (0.3–3.0)               | 0.3 (0.1–0.6)                | 0.478   |
| ESR at diagnosis, mm/hr        | 36 ± 22                     | 21 ± 16                      | 0.043   |
| FC at diagnosis, mg/kg         | 1,000 ± 62                  | 949 ± 918                    | 0.876   |

Data are expressed as means ± standard deviation for continuous variables that showed normal distribution, and median (interquartile range) for continuous variables that did not show normal distribution, unless otherwise indicated.

EIM = extraintestinal manifestation, UC = ulcerative colitis, E1 = ulcerative proctitis, E2 = left-sided UC (distal to splenic flexure), E3 = extensive (hepatic flexure distally), E4 = pancolitis (proximal to hepatic flexure), S0 = never severe (PCDAI < 65), S1 = ever severe (PCDAI ≥ 65), PCDAI = Pediatric Ulcerative Colitis Activity Index, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, FC = fecal calprotectin.
monitoring and treatment adjustment may minimize the occurrence of EIMs in Korean children and adolescents with UC. Moreover, the finding that PUCAI scores at diagnosis were not significantly different between the EIM-positive and -negative groups in the patients with UC indicates the importance of close monitoring of EIMs in addition to the assessment of PUCAI scores, which are used in everyday clinical practice.

Several studies show that the disease severity at diagnosis is related to EIM development in pediatric patients with IBD. In the study of Dotson et al., increased disease severity was associated with the occurrence of EIMs. Their study used the Physician Global Assessment, PCDAI, modified PCDAI, PUCAI, and ESR to assess disease severity; they found that the related EIMs were arthralgia \( (P = 0.024) \), aphthous stomatitis \( (P = 0.001) \), and erythema nodosum \( (P = 0.009) \). These authors also found that aphthous stomatitis, erythema nodosum, and sclerosing cholangitis showed significantly different rates between CD and UC. Similarly, in our study the occurrence of EIMs was related with only the disease severity of UC based on the Paris classification \( (P = 0.012) \), and EIMs were significantly more frequent in CD than in UC. However, we were unable to identify significant differences between EIM types due to the small number of EIM occurrences and could not find any association between PCDAI or PUCAI scores at diagnosis with EIM development.
Intestinal inflammation in IBD is not stable but can change dynamically according to environmental factors, such as diet or medication, and consequently can change the host’s immunological balance. Additionally, PCDAI or PUCAI scores represent the patient’s disease activity at a single time point. Similarly, the Paris classification for CD patients is assessed at diagnosis. Thus, these factors represent cross-sectional disease activity rather than longitudinal disease activity. Meanwhile, the disease severity checked in the Paris classification for UC assesses continuous disease activity from diagnosis to assessment. This longitudinal characteristic of the disease severity checked in the Paris classification may have been why only it was associated with the EIM development in this study.

Another recent study reported that disease severity at diagnosis was associated with future outcomes in children with UC. Assa et al.\textsuperscript{18} have demonstrated that the severity of UC at diagnosis, but not disease extent, was associated with the risk of colectomy, hospitalization, flares, and biological therapy. These authors found that the EIMs were related to colonic involvement in patients with CD; however, they did not find any associations between disease severity at diagnosis and EIMs in both CD and UC.

More recently, Jansson et al.\textsuperscript{19} reported that EIMs are associated with future disease severity in pediatric IBD, finding that EIMs in UC increased the risk of biological treatment and surgery, and EIMs in CD increased the relapse rate. These results support those in studies done with French and Swiss pediatric IBD patients.\textsuperscript{20,21} Other studies have reported that the presence of EIMs and a higher PUCAI score at diagnosis were related with extent progression over time since the diagnosis of pediatric UC,\textsuperscript{22} suggesting that EIMs in UC are closely related to intestinal disease activity progression, which could be an index of suspicion indicating the need for more investigation of progression.

The current study has some limitations. First, the study’s retrospective nature may have resulted in selection and observational bias and may have limited accurate data collection. Second, although ours was a multicenter study in one Korean province, the total number of patients was not large enough to reflect the various EIMs that can develop during the disease course. This may be why associations between EIMs and disease severity were not observed in patients with CD in this study. Moreover, it is always intriguing to define the range of EIMs because it is not always clear what an EIM is and what a medication side-effect is. We tried to define the range of EIMs as strictly as possible; however, some data could be missing because of the retrospective nature of the study. This may be the reason why all the patients in this study had only one EIM. A short follow-up period may have also influenced this finding.

Third, the follow-up period of patients in this study was rather short for observation of EIMs that occur during the natural disease course of IBD. Due to the nature of inflammatory bowel disease, which requires continuous monitoring after diagnosis, a sufficient follow-up period from diagnosis to the onset of EIM is required to ensure the validity of the study results. Fourth, we did not investigate the timing of EIM occurrence or the association between EIM and the current medication at the time of EIM development. Hence, we were unable to investigate factors associated with the time-to-EIM development. A prospective population-based study is needed to examine the precise incidence and natural course of EIMs in Korean pediatric patients with IBD. Furthermore, considering the difference of IBD phenotype between ethnicities,\textsuperscript{23} a multinational study should better reveal the potential differences of EIM occurrence and type between different descent.
In conclusion, severe disease activity based on the Paris classification in pediatric patients with UC was significantly associated with the EIM development. As disease severity in the Paris classification is a dynamic parameter, close disease activity monitoring and treatment adjustment may minimize the occurrence of EIMs in Korean children and adolescents with UC.

**REFERENCES**

1. Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. *JAMA Pediatr* 2015;169(11):1053-60. [PUBMED] [CROSSREF]

2. Jose FA, Heyman MB. Extraintestinal manifestations of inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2008;46(2):124-33. [PUBMED] [CROSSREF]

3. Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? *World J Gastroenterol* 2011;17(22):2702-7. [PUBMED] [CROSSREF]

4. Jose FA, Garnett EA, Vittinghoff E, Ferry GD, Winter HS, Baldassano RN, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2009;15(1):63-8. [PUBMED] [CROSSREF]

5. Hyams JS. Extraintestinal manifestations of inflammatory bowel disease in children. *J Pediatr Gastroenterol Nutr* 1994;19(1):7-21. [PUBMED] [CROSSREF]

6. Jang HJ, Kang B, Choe BH. The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults. *Transl Pediatr* 2019;8(1):4-15. [PUBMED] [CROSSREF]

7. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. *World J Gastroenterol* 2006;12(30):4819-31. [PUBMED] [CROSSREF]

8. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. *J Clin Gastroenterol* 1996;23(1):29-34. [PUBMED] [CROSSREF]

9. Šýkora J, Pomahačová R, Kreslová M, Cvalínová D, Štych P, Schwarz J. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. *World J Gastroenterol* 2018;24(25):2741-63. [PUBMED] [CROSSREF]

10. Hong SJ, Cho SM, Choe BH, Jang HJ, Choi KH, Kang B, et al. Characteristics and incidence trends for pediatric inflammatory bowel disease in Daegu-Kyungpook province in Korea: a multi-center study. *J Korean Med Sci* 2018;33(18):e132. [PUBMED] [CROSSREF]

11. Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. *J Pediatr Gastroenterol Nutr* 2014;58(6):795-806. [PUBMED] [CROSSREF]

12. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. *Inflamm Bowel Dis* 2011;17(6):1314-21. [PUBMED] [CROSSREF]

13. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a pediatric Crohn’s disease activity index. *J Pediatr Gastroenterol Nutr* 1991;12(4):439-47. [PUBMED] [CROSSREF]

14. Turner D, Griffiths AM, Walters TD, Seab T, Markowitz J, Pfefferkorn M, et al. Appraisal of the pediatric Crohn’s disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. *Am J Gastroenterol* 2010;105(9):2085-92. [PUBMED] [CROSSREF]

15. Turner D, Otley AR, Mack D, Hyams J, de Bruyne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. *Gastroenterology* 2007;133(2):423-32. [PUBMED] [CROSSREF]
16. Dotson JL, Hyams JS, Markowitz J, LeLeiko NS, Mack DR, Evans JS, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr 2010;51(2):140-5. [PUBMED] [CROSSREF]

17. Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg 2017;26(6):349-55. [PUBMED] [CROSSREF]

18. Assa A, Rinawi F, Shamir R. The long-term predictive properties of the Paris classification in paediatric inflammatory bowel disease patients. J Crohns Colitis 2018;12(1):39-47. [PUBMED] [CROSSREF]

19. Jansson S, Malham M, Paerregaard A, Jakobsen C, Wewer V. Extraintestinal manifestations are associated with disease severity in pediatric onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2020;71(1):40-5. [PUBMED] [CROSSREF]

20. Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease: prevalence, presentation, and anti-TNF treatment. J Pediatr Gastroenterol Nutr 2017;65(2):200-6. [PUBMED] [CROSSREF]

21. Duricova D, Leroyer A, Savoye G, Sarter H, Pariente B, Aoucheta D, et al. Extra-intestinal manifestations at diagnosis in paediatric- and elderly-onset ulcerative colitis are associated with a more severe disease outcome: a population-based study. J Crohns Colitis 2017;11(11):1326-34. [PUBMED] [CROSSREF]

22. Rinawi F, Assa A, Hartman C, Mozer Glassberg V, Nachmias Friedler V, Rosenbach Y, et al. Long-term extent change of pediatric-onset ulcerative colitis. J Clin Gastroenterol 2018;52(4):326-32. [PUBMED] [CROSSREF]

23. Kang B, Kim JE, Jung JH, Choe JY, Kim MJ, Choe YH, et al. Korean Children and adolescents with Crohn’s disease are more likely to present with perianal fistulizing disease at diagnosis compared to their European counterparts. Pediatr Gastroenterol Hepatol Nutr 2020;23(1):49-62. [PUBMED] [CROSSREF]